Search tips
Search criteria

Results 1-4 (4)

Clipboard (0)
more »
Year of Publication
1.  Neoadjuvant Therapy – What Have We Achieved in the Last 20 Years? 
Breast Care  2011;6(6):419-426.
Neoadjuvant chemotherapy is the standard of care for patients with large, inoperable tumors or inflammatory breast cancer, but it is also increasingly considered for women with operable disease. Several randomized trials have demonstrated that anthracycline- and taxane-containing regimens in operable breast cancer were equally effective in terms of disease-free or overall survival regardless of whether they were administered postoperatively or preoperatively. Further neoadjuvant treatment allows for a higher rate of breast conserving surgery. Tumor responses in terms of pathologic complete remission after short-term chemotherapy will probably only serve as a surrogate marker for long-term outcome in some molecular breast cancer subtypes like the triple-negative, HER2-positive, and some luminal B subsets. Recent trials showed that in HER2-positive disease pCR rates were as high as 70% when 2 HER2-targeted agents were added to chemotherapy.
PMCID: PMC3290030  PMID: 22419894
Neoadjuvant chemotherapy; Pathologic complete remission; Molecular subtypes; HER2-positive breast cancer
3.  The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer 
Breast Care  2009;4(6):367-372.
Metastatic breast cancer (MBC) is usually not curable, and the primary goals of treatment are thus to control disease and symptoms, maintain quality of life, and prolong life while minimizing toxicity. Chemotherapy is still an important treatment option in MBC, and the decision whether polychemotherapy is preferable to sequential monochemotherapy is under debate. Data are quite consistent in that response rates and time to progression are significantly increased with combination chemotherapy compared to the use of a single agent in MBC patients. Data regarding overall survival with polychemotherapy are not conclusive; however, frequently this approach was associated with increased treatment toxicity and decreased quality of life. Nonetheless, in patients with symptomatic or acute, life-threatening disease, where maximum and quick tumor remission is important, polychemotherapy should be the preferred approach. Furthermore, since some of the newer combination regimens seem to increase toxicity only slightly and substantially prolong time to progression, this approach may also be an option in patients without symptomatic disease.
PMCID: PMC2941999  PMID: 20877671
Breast cancer; Metastasis; Polychemotherapy
4.  Dose-Dense Therapy 
Breast Care  2008;3(2):134-138.
PMCID: PMC2931089  PMID: 21373218

Results 1-4 (4)